ArticleAmerican journal of cancer research2025
Global, regional, and national burden of premenopausal and postmenopausal malignant melanoma from 1990 to 2021: a comprehensive cross-sectional analysis.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Life Factors and Melanoma: From the Macroscopic State to the Molecular Mechanism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant melanoma is a highly fatal disease closely associated with sex hormones. This study aimed to evaluate the global burden and trends of malignant melanoma based on menopausal status. Data on the prevalence, disability-adjusted life years (DALYs), and mortality of malignant melanoma were obtained from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021. Age 55 was used as a threshold for menopausal status to assess global, regional, and national trends in disease burden among women. In 2021, the age-standardized prevalence rate (ASPR) of malignant melanoma was higher in women than men under 55 years but lower in women over 55 years. From 1990 to 2021, the ASPR for premenopausal women increased from 14.23 [95% uncertainty interval (UI) (13.79-14.60)] to 16.53 [95% UI (15.09-17.78)], while the age-standardized DALYs rate (ASDR) decreased from 14.04 [95% UI (12.20-15.61)] to 11.83 [95% UI (9.20-14.35)], and the age-standardized mortality rate (ASMR) decreased from 0.27 [95% UI (0.24-0.30)] to 0.23 [95% UI (0.18-0.28)]. For postmenopausal women, the ASPR increased from 55.01 [95% UI (51.71-57.23)] to 81.43 [95% UI (74.33-87.03)], while the ASDR decreased from 63.88 [95% UI (58.39-69.64)] to 56.11 [95% UI (48.79-63.66)], and the ASMR decreased from 2.96 [95% UI (2.69-3.19)] to 2.73 [95% UI (2.36-3.07)]. The disease burden was highest in high socio-demographic index (SDI) regions but has recently decreased, whereas a gradual increase was observed in high-middle SDI regions. At the national level, New Zealand had the highest ASPR for both premenopausal and postmenopausal women, with values of 245.63 [95% UI (209.56, 279.91)] and 909.37 [95% UI (754.63, 1037.39)], respectively. Regional variations in population-level determinants of disease burden were identified. The risk and prognosis of malignant melanoma in women may differ by menopausal status due to the interplay of sex hormones and the immune system. Further research is needed to develop tailored screening and treatment strategies for women across diverse SDI regions and menopausal statuses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.